BMSSC
SRPT icon

B. Metzler seel. Sohn & Co’s Sarepta Therapeutics SRPT Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,055
Closed -$769K – 753
2025
Q1 		$769K Hold
12,055
– – 0.01% 573
2024
Q4 		$1.47M Buy
+12,055
New +$1.48M 0.02% 447
2021
Q1 		– Sell
-1,242
Closed -$213K – 698
2020
Q4 		$213K Buy
+1,242
New +$184K ﹤0.01% 642

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

B. Metzler seel. Sohn & Co's SRPT Position: Q2 2025 in Review

B. Metzler seel. Sohn & Co sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 12,055 shares — an estimated $769K sold.

B. Metzler seel. Sohn & Co first reported a position in SRPT in Q4 2020 and held it in 3 quarters. The position peaked at $1.47M in Q4 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • B. Metzler seel. Sohn & Co reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 12,055 Sarepta Therapeutics shares in Q2 2025, an estimated $769K.
  • B. Metzler seel. Sohn & Co first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 3 quarters.
  • B. Metzler seel. Sohn & Co's Sarepta Therapeutics position peaked at $1.47M in Q4 2024.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2025, filed 11 Aug 2025.